Company intelligence / Profile preview

Weike Medical

Wuhan, Hubei, China

Ownership: Private
Development stage: Other

Overview

Weike Medical has developed several innovative cardiovascular devices, including the D-shant® atrial shunt (received FDA Breakthrough Device Designation in 2023), D-shufo™ patent foramen ovale occluder, and a transcatheter aortic valve replacement system. The company holds over 60 patents and focuses on minimally invasive interventions for heart failure and structural heart disease. Its products have achieved significant regulatory milestones in China and the US

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Weike Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weike Medical.

Explore the full profile